Loading…
NovaBridge Biosciences is projected to rise to $1.66 by 2027, a +4% move from its current price of $1.60. NBP is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $1.55 | $1.60 | $1.66 | +0.04% |
| Aug 5 | $1.53 | $1.60 | $1.68 | +0.09% |
| Aug 6 | $1.51 | $1.60 | $1.70 | +0.13% |
| Aug 7 | $1.50 | $1.60 | $1.72 | +0.17% |
| Aug 8 | $1.48 | $1.60 | $1.73 | +0.22% |
| Aug 9 | $1.47 | $1.60 | $1.75 | +0.26% |
| Aug 10 | $1.47 | $1.60 | $1.76 | +0.31% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.47 | $1.60 | $1.76 | +0.31% |
| Week 2 | $1.42 | $1.61 | $1.83 | +0.61% |
| Week 3 | $1.38 | $1.61 | $1.89 | +0.92% |
| Week 4 | $1.35 | $1.62 | $1.94 | +1.23% |
| Week 5 | $1.33 | $1.62 | $1.99 | +1.54% |
| Week 6 | $1.30 | $1.63 | $2.04 | +1.85% |
| Week 7 | $1.28 | $1.63 | $2.08 | +2.16% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NovaBridge Biosciences is a biotechnology company that engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology, and its product pipeline includes givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors.
It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
NovaBridge Biosciences (NBP) is currently priced at $1.61 per share and has a market capitalization of $186.19M, ranking 3834 by market cap. The stock trades in a sector focused on healthcare and biotechnology, with a pipeline that spans oncology and ophthalmology indications. The near-term outlook shows neutral momentum, while the longer horizon indicates a bullish path as indicated by the year-by-year forecast.
The current price sits near the center of a forecast that envisions gradual gains through the late 2020s and meaningful upside in the 2030s and beyond, with potential to reach substantially higher levels by 2050.
A major floor 30.8% below — a decisive break under it would weaken the trend.
The nearest floor, 6.3% below — buyers have tended to step in here.
The nearest ceiling, 33.8% above — a clean break opens room to run.
A major ceiling 68.8% above — clearing it would confirm fresh momentum.
Key NBP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NBP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.68 | Sell | $1.66 | Sell |
| MA 10 | $1.73 | Sell | $1.71 | Sell |
| MA 20 | $1.80 | Sell | $1.75 | Sell |
| MA 50 | $1.74 | Sell | $1.85 | Sell |
| MA 100 | $2.10 | Sell | $2.16 | Sell |
| MA 200 | $3.06 | Sell | $2.51 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 37.62 | Neutral |
| Stoch RSI (14) | 2.56 | Buy |
| CCI (20) | -164.25 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -13.51 | Sell |
| Bollinger %B (20,2) | 0.03 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.05 | Sell |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 29.82 | Buy |
| Momentum (10) | -0.18 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 1.60 | Sell |
| ADX (14) | 15.67 | Neutral |
| ATR (14) | 0.05 | Info |
In the near term, the 30-day technical picture is Bearish. The RSI(14) is 40, and the stock’s short-term moving averages show the SMA50 at $1.75 and the SMA200 at $3.10. A near-term support level sits at $1.50 and a resistance at $2.14.
The stock has traded within a 30-day range of $1.27 to $2.04, reflecting cautious near-term momentum. Annualized volatility stands around 70%, underscoring elevated price swings over the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.47 | $1.60 | $2.25 | 0% | Neutral | |
| $1.29 | $1.66 | $2.27 | +4% | Neutral | |
| $1.22 | $1.62 | $2.32 | +1% | Neutral | |
| $1.29 | $1.77 | $2.62 | +11% | Neutral | |
| $1.19 | $1.68 | $2.57 | +5% | Neutral | |
| $1.38 | $2.00 | $3.13 | +25% | Bullish | |
| $1.62 | $2.40 | $3.85 | +50% | Bullish | |
| $1.60 | $2.42 | $3.96 | +51% | Bullish | |
| $1.73 | $2.68 | $4.47 | +67% | Bullish | |
| $1.65 | $2.60 | $4.41 | +62% | Bullish | |
| $2.21 | $3.82 | $6.97 | +139% | Bullish | |
| $3.01 | $6.13 | $12.43 | +283% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.47 | $1.60 | $2.02 | +0.00% |
| September 2026 | $1.41 | $1.68 | $2.06 | +4.77% |
| October 2026 | $1.38 | $1.66 | $2.08 | -0.68% |
| November 2026 | $1.43 | $1.73 | $2.18 | +3.81% |
| December 2026 | $1.45 | $1.77 | $2.25 | +2.48% |
Click any year to see its month-by-month NBP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NBP is projected to trade between $1.47 and $2.25, averaging $1.60 — a potential gain of 0% from today's $1.60. A consolidation phase looks the most probable path here.
NovaBridge Biosciences's 2027 outlook centres on $1.66, within a $1.29 to $2.27 range. That is up +4% on the projected 2026 average. That marks a +4% change versus current levels. Price action looks broadly range-bound.
By 2028, NBP could reach as high as $2.32, with a base case around $1.62 and support toward $1.22 — roughly +1% from $1.60. A consolidation phase looks the most probable path here.
Expect NBP to range from $1.29 to $2.62 through 2029. The $1.77 average target implies a +11% move from current prices. That is up +9% on the projected 2028 average. Price action looks broadly range-bound.
The NBP price prediction for 2030 points to an average of $1.68 (low $1.19, high $2.57) — a potential gain of +5% on today's $1.60. A consolidation phase looks the most probable path here.
In 2031, NBP is projected to trade between $1.38 and $3.13, averaging $2.00 — a potential gain of +25% from today's $1.60. That is up +19% on the projected 2030 average. Momentum favours further upside here.
NovaBridge Biosciences's 2032 outlook centres on $2.40, within a $1.62 to $3.85 range. That is up +20% on the projected 2031 average. That marks a +50% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, NBP could reach as high as $3.96, with a base case around $2.42 and support toward $1.60 — roughly +51% from $1.60. Momentum favours further upside here.
Expect NBP to range from $1.73 to $4.47 through 2034. The $2.68 average target implies a +67% move from current prices. That is up +11% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The NBP price prediction for 2035 points to an average of $2.60 (low $1.65, high $4.41) — a potential gain of +62% on today's $1.60. Momentum favours further upside here.
In 2040, NBP is projected to trade between $2.21 and $6.97, averaging $3.82 — a potential gain of +139% from today's $1.60. That is up +47% on the projected 2035 average. Buyers look set to stay in control over this stretch.
NovaBridge Biosciences's 2050 outlook centres on $6.13, within a $3.01 to $12.43 range. That is up +61% on the projected 2040 average. That marks a +283% change versus current levels. Momentum favours further upside here.
Investing $1,000 in NBP today (≈ 625 NBP) could be worth
$3,832.01
+$2,832.01 (+283%) by 2050 · US Dollar
Based on the average projected NBP price of $6.13 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NBPwould be worth at today's price.
$1,000 invested in NBP on Jul 31, 2025 (≈ 497.51244 NBP) would be worth
$796.02
-$203.98 (-20.4%) today · 0.80× · US Dollar
Based on a NBP entry price of $2.01 vs. today's $1.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.77 | $903.95 | -9.6% |
| 1 month ago | $1.99 | $804.02 | -19.6% |
| 3 months ago | $2.38 | $672.27 | -32.8% |
| 6 months ago | $3.43 | $466.47 | -53.4% |
| 1 year ago | $2.01 | $796.02 | -20.4% |
| All time (5.0y) ago | $76.85 | $20.82 | -97.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NBP forecast.
Our base-case forecast reaches $3.20 around 2040.
Implied market cap at $3.20: $370.08M
The multi-year forecast shows a transition from neutral to bullish over time. For 2031 the average price is projected at $1.99 with a 23.5% ROI, and a bullish sentiment follows through 2032 at $2.39 with 48.7% ROI and 2033 at $2.40 with 49.2% ROI. The momentum continues into 2034 with an average of $2.68 and 66.4% ROI, and 2035 at $2.57 with 59.7% ROI.
By 2040 the average rises to $3.81 with 136.5% ROI, and by 2050 the average reaches $6.02 with 274% ROI. The forecast also shows a rise in max values across years, with later years exhibiting stronger upside potential (e.g., max approaching significantly higher levels). These numbers suggest a long-run bullish trajectory, tempered by near-term uncertainty and market dynamics.
Tap a question to reveal the answer.
Avg $1.66, min $1.16, max $2.57, ROI 3.1%, sentiment NEUTRAL.
The near-term forecast is NEUTRAL with 2026 avg $1.61, 2027 avg $1.66, 2028 avg $1.62, 2029 avg $1.76, 2030 avg $1.66. From 2031 onward the outlook shifts to BULLISH, with 2031 avg $1.99 (ROI 23.5%), 2040 avg $3.81 (ROI 136.5%), and 2050 avg $6.02 (ROI 274%). These are estimates, not guarantees.
Yes. The forecast lists a max of $12.45 by 2050.
Current price is $1.61.
From 2031 onward, the forecast is bullish, with 2031 avg $1.99 and 2032 avg $2.39 and 2033 avg $2.40, leading to 2040 avg $3.81 and 2050 avg $6.02. ROI progresses from 23.5% in 2031 to 274% in 2050, indicating substantial upside potential under the forecast.
NovaBridge Biosciences Community Discussion
0Share your NovaBridge Biosciences price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.